Company Overview and News
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction.
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.
TSS WEX BR DLPH
Total System Services, Inc. (TSS - Free Report) has been consistently riding high over the past few years, primarily driven by its series of solid acquisitions. One of its recent buyouts is iMobile3, a provider of private-labelled, small business solutions in the payments industry. This buyout enables the company to offer the best possible payment tools to its customers. Another notable acquisition was of NetSpend in July 2013, which made Total System one of the largest program managers of dollars reloaded in prepaid cards, enhancing its footprint in the U.
TSS ALLY WEX CATM EVTC
Have you been paying attention to shares of NV5 Global (NVEE - Free Report) ? Shares have been on the move with the stock up 8.4% over the past month. The stock hit a new 52-week high of $92.5 in the previous session. NV5 Global has gained 66.1% since the start of the year compared to the 18.3% move for the Zacks Business Services sector and the 16% return for the Zacks Consulting Services industry.
TSS RHI ALLY NVEE CRAI
Have you been paying attention to shares of Total System Services (TSS - Free Report) ? Shares have been on the move with the stock up 5.9% over the past month. The stock hit a new 52-week high of $99.4 in the previous session. Total System Services has gained 25.1% since the start of the year compared to the 18.3% move for the Zacks Business Services sector and the 23.3% return for the Zacks Financial Transaction Services industry.
Global Payments Inc. (GPN - Free Report) recently announced the completion of its pending acquisition of AdvancedMD from Marlin Equity Partners. On closure, the buyer company expects the transaction to contribute nearly $7-$8 million revenues. However, the acquirer anticipates no positive effect on its earnings per share. AdvanceMD is a leading provider of cloud-based software as a service or SaaS solutions to small-to-medium-sized physician practices in the United States.
TSS SWX GPN KHC CATM EVTC
Global Payments Inc. (GPN - Free Report) has been emphasizing on acquisitions to expedite growth. A number of buyouts made in recent years added to the company’s scale and size. One of the most notable among these is the purchase of Heartland Payments Systems (completed in 2016). The merger significantly expanded Global Payments’ small and medium-sized enterprise distribution, merchant base and vertical reach in the United States.
TSS GPN WEX CATM
Republic Services, Inc. (RSG - Free Report) is benefitting from internal growth, increased operational efficiency as well as consistent record of rewarding shareholders in the form of dividend and share repurchases.
TSS G RSG WEX
U.S. retail sales for the first six months of 2018 have increased year over year, primarily led by higher wages from a tight labor market, higher savings and tax cuts. Increase in retail sales obviously means higher spending by Americans. The level of spending by consumers drives another industry -- the payments industry or payment processors -- which include a wide range of companies from ATM service providers to payment networks, debit and credit card companies and more.
TSS V WEX CATM
Shares of S&P Global Inc. (SPGI - Free Report) have gained a massive 33.5% in a year’s time, outperforming the 26.5% rally of the industry it belongs to.We believe that the company has the potential to carry on with this outperformance, moving ahead.
TSS G SPGI WEX
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to TSS / Total System Services, Inc. on message board site Silicon Investor.
as of ET